Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 7/20 | 0.42 |
| ▸ | PPARD | Q03181 | 7/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2721342 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL26900519 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18738574 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL25576277 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2948540 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15158837 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2951087 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16420210 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL22445018 | 1.00 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL260630 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250242037-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250009893-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12121585-B2 | Dendrimer compositions and methods for drug delivery to the eye | Ashvattha Therapeutics, Inc. (US) | 2024-10-22 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-118159295-A | Dendrimer conjugates and methods of use thereof | 阿什瓦塔治疗股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| EP-4351652-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240058459-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11612660-B2 | Dendrimer compositions and methods for drug delivery to the eye | Ashvattha Therapeutics, Inc. (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2022261504-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4069308-A2 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| WO-2021113662-A2 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | Ashvattha Therapeutics, Inc. (US) | 2021-06-10 | — | — | WO | disclosed |
| US-20210170039-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | PROGRAMMABLE MEDICINE OPERATING COMPANY | 2021-06-10 | — | — | US | disclosed |
| EP-1886759-B1 | WATER-SOLUBLE PREFLUX AND USE THEREOF | SHIKOKU CHEM (JP) | 2016-10-05 | — | — | EP | disclosed |
| EP-2170890-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2011-10-26 | — | — | EP | disclosed |
| US-7754105-B2 | Water-soluble preflux and usage of the same | SHIKOKU CHEMICALS CORPORATION (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20080318070-A1 | Water-Soluble Preflux and Usage of the Same | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1886759-A1 | WATER-SOLUBLE PREFLUX AND USE THEREOF | SHIKOKU CHEMICALS CORPORATION (JP) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | FFAR3 3754/4885HDAC3 1339/4885HDAC1 1716/4885 |
| US-20240058459-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | FLT4, KDR, FLT1 | FFAR3 339/4885HDAC3 658/4885HDAC1 954/4885 |
| US-12121585-B2 | Dendrimer compositions and methods for drug delivery to the eye | FLT4, KDR, FLT1 | FFAR3 339/4885HDAC3 658/4885HDAC1 954/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | FFAR3 4690/4885HDAC3 1547/4885HDAC1 924/4885 |
| US-20250242037-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | FLT4, KDR, FLT1 | FFAR3 339/4885HDAC3 658/4885HDAC1 954/4885 |
| US-20210170039-A1 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO THE EYE | FLT4, KDR, FLT1 | FFAR3 339/4885HDAC3 658/4885HDAC1 954/4885 |
| US-20250009893-A1 | DENDRIMER CONJUGATES AND METHODS OF USE THEREOF | PAICS, CD47, CD44 | FFAR3 2936/4885HDAC3 1973/4885HDAC1 3938/4885 |
| US-11612660-B2 | Dendrimer compositions and methods for drug delivery to the eye | FLT4, KDR, FLT1 | FFAR3 339/4885HDAC3 658/4885HDAC1 954/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | FFAR3 349/4885HDAC3 3637/4885HDAC1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.